期刊文献+

假瘤样脱髓鞘病变—脊髓手术的误区 被引量:3

Tumefactive demyelinating lesions:a pitfall of inspinal cord surgery
下载PDF
导出
摘要 目的脊髓的假瘤样脱髓鞘病变(TDLs)与肿瘤之间的鉴别非常困难。由于两种疾病的治疗方法不同,对于脊髓TDLs的误诊往往导致了严重的后果。方法对5例收治的脊髓TDLs的患者进行了总结,从临床资料、影像学表现、治疗方法及预后进行归纳分析。结果患者的平均年龄为50.4岁;主要临床表现包括:肢体肌力下降、疼痛及麻木等;脊柱所有节段均可能受累及;影像学表现包括:占位效应、病灶周边水肿、不规则环形强化等;1例接受病灶活检,另外4例接受病灶手术切除;术中冰冻病理无法正确判断病理类型;在病理结果证实为TDLs后,所有患者均接受了激素治疗;所有患者对激素治疗反应良好,随访中未见病灶复发及症状加重。结论由于不同的诊断会直接导致不同的治疗手段,因此对于脊髓内占位性病变的诊断及治疗需要谨慎处理:术前应尽量完善各种辅助检查;术中以保留正常脊髓功能为主,不追求病灶全切除,并可进行活检;在病理分析遇到困难时应寻求神经病理学帮助;对于术前高度怀疑为脊髓TDLs的患者可考虑给予诊断性激素治疗,但需从临床及影像学方面密切动态观察。 Objective Differential diagnosis between tumefactive demyelinating lesions (TDLs) and neoplasms in the spinal cord is digicult. Misdiagnosis usually worsens the outcome because of different treatments. The clinical and radiological data, treatment and prognosis of 5 cases of TDLs in the spinal cord were investigated. Results The mean age of onset in these patients was 50. 4 years, and the main clinical symptoms included limb weakness, pain, and numbness, suggesting that the lesions may affect all the segments. Radiological examinations showed mass effect, perifocal edema, and enhancement. One patient received a biopsy, followed by and homaone therapies. Surgery was performed in the other 4 patients who received hormone therapy after pathological diagnosis. Although intra-operative frozen section analysis failed to confirm the diagnosis of TDLs, these patients responded well to hormone and immunosuppressive therapies. No relapse was found in the follow-up. Conclusion Since different diagnoses lead to different outcomes, spinal cord lesions should be carefully diagnosed. Preoperative examination should be consummate, and functions should be reserved during intraoperative resection; a diagnostic hormonal therapy could be used but strict observation should be performed in both clinical and imaging.
出处 《中华神经外科疾病研究杂志》 CAS 2014年第1期51-54,共4页 Chinese Journal of Neurosurgical Disease Research
基金 上海市科学技术委员会基金资助项目(11140903802) 长海医院1255科研基金资助项目(CH125520904)
关键词 瘤样脱髓鞘病变 脊髓 活检 激素治疗 肿瘤 Tumefactive demyelinating lesions Spinal cord Biopsy Hormone therapy Neoplasm
  • 相关文献

参考文献12

  • 1Tan HM,Chan LL,Chuab KL. Monophasic,solitary tumefactive demyelinating lesion:neuroimaging features and neuropathological diagnosis[J].{H}British Journal of Radiology,2004,(914):153-156.
  • 2Given CA 2nd,Stevens BS,Lee C. The MRI appearance of tumefactive demyelinating lesions[J].AJR Am J Reentgenol,2004,(1):195-199.
  • 3Fallah A,Banglawala S,Ebrahim S. Case Series:tumefactive demyelinating lesions:a diagnostic challenge[J].{H}CANADIAN JOURNAL OF SURGERY,2010,(1):69-70.
  • 4Xia L,Lin S,Wang ZC. Tumefactive demyelinating lesions:nine cases and a review of the literature[J].{H}NEUROSURGICAL REVIEW,2009,(2):171-179.
  • 5Yaghi S,Gokdin M,Sethi H. Tumefactive demyelination of the spinal cord[J].{H}ACTA NEUROLOGICA BELGICA,2010,(2):206-208.
  • 6Sugita Y,Terasaki M,Shigemori M. Acute focal demyelinating disease simulating brain tumors:histopathologic guidelines for an accurate diagnosis[J].{H}NEUROPATHOLOGY,2001,(1):25-31.
  • 7Cha S,Pierce S,Knopp EA. Dynamic contrast-enhanced T2 *-weighted MR imaging of tumefactive demyelinating lesions[J].{H}AJNR American Journal of Neuroradiology,2001,(6):1109-1116.
  • 8Jain R,Ellika S,Lehman NL. Can permeability measurements add to blood volume measurements in differentiating tumefactive demyelinating lesions from high grade gliomas using perfusion CT[J].{H}Journal of Neuro-Oncology,2010,(3):383-388.
  • 9Hourani R,Brant LJ,Rizk T. Can proton MR spectroscopic and perfusion imaging differentiate between neoplastic and nonneoplastic brain lesions in adults[J].{H}AJNR American Journal of Neuroradiology,2008,(2):366-372.
  • 10Cianfoni A,Niku S,Imbesi SG. Metabolite findings in tumefactive demyelinating lesions utilizing short echo time proton magnetic resonance spectroscopy[J].{H}AJNR American Journal of Neuroradiology,2007,(2):272-277.

同被引文献47

  • 1陈慧敏.中枢神经肿瘤样脱髓鞘病[J].现代实用医学,2005,17(10):600-601. 被引量:6
  • 2Lucchinetti CF, Gavrilova RH, Metz I, et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis[J]. Brain, 2008, 131 (7) : 1759-1775.
  • 3Yiu EM, Laughlin S, Verhey LH, et al. Clinical and Magnetic Resonance Imaging (MRI) Distinctions Between Tumefactive Demyelination and Brain Tumors in Children[J].J Child Neurol, 2014,29(5) :654-665.
  • 4Takeuchi T, Ogura M, Sato M, et al. Late-onset tumefactive multiple sclerosis[J]. Radiat Med, 2008, 26:549-552.
  • 5Altintas A, Petek B, Isik N, et al. Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study[J]. Mul SclJ, 2012,18(10) :1448-1453.
  • 6Tsui EYK, Leung WH, ChanJH, et al. Tumefactive demyelinating lesions by combined perfusion-weighted and diffusion weighted imaging[J]. Comput Med Imaging Graph, 2002, 26 (5) :343-346.
  • 7Hyland M, Bermel RA, CohenJA. Restricted diffusion preceding gadolinium enhancement in large or umefactive demyelinating lesions[J]. Neurol Clin Pract, 2013, 3(1) :15-21.
  • 8Low CK, Lim WEH, Rumpel H. Differentiating tumefactive demyelinating lesion from neoplasm-Does physiologic MR imaging help?[J]. Radiography, 2011,17:76-80.
  • 9Cianfoni A, Niku S, Imbesi SG. Metabolite fi ndings in tumefactive demyelinating lesions utilizing short echo time proton magnetic resonance spectroscopy[J]. AJNR, 2007, 28 :272-277.
  • 10SainiJ, Chatterjee S, Thomas B, et al. Conventional and advanced magnetic resonance imaging in tumefactive demyelination[J]. Acta Radiol, 2011, 52(10) :1159-1168.

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部